Chi-Ping  Day, Ph.D.

Chi-Ping Day, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


The goal of Dr. Day's research is to identify driving factors of progression and therapeutic response in cancer by integrative modeling approach, especially using genetically engineered mouse models and computational models, a "reiterate (real) mouse-to-(computer) mouse" strategy.

Areas of Expertise

1) cancer modeling 2) metastatic melanoma 3) preclinical study of immunotherapy


Selected Key Publications

Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy

Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G.
Nature Medicine. 26(5): 781-791, 2020. [ Journal Article ]

Melanoblast transcriptome analysis reveals novel pathways promoting melanoma metastasis

Marie KL, Sassano A, Yang HH, Michalowski AM, Michael HT, Guo T, Tsai YC, Weissman AM, Lee MP, Jenkins LM, Zaidi MR, Pérez-Guijarro E, Day CP, Arnheiter H, Davis S, Meltzer PS, Merlino G, Mishra PJ.
Nature Communications. 11(1): 333, 2020. [ Journal Article ]

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

Day CP, Merlino G, Van Dyke T.
Cell. 163(1): 39-53, 2015. [ Journal Article ]

"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts

Day CP, Carter J, Weaver Ohler Z, Bonomi C, El Meskini R, Martin P, Graff-Cherry C, Feigenbaum L, Tüting T, Van Dyke T, Hollingshead M, Merlino G.
PLoS One. 9(11): e109956, 2014. [ Journal Article ]

Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study

Day CP, Carter J, Bonomi C, Esposito D, Crise B, Ortiz-Conde B, Hollingshead M, Merlino G.
Pigment Cell Melanoma Res. 22(3): 283-95, 2009. [ Journal Article ]